

## Sanford Health South Region Pediatric Antibigram Gram Negative Organisms

2026 Pediatric Antibiogram (Jan-Dec 2025 data)	<i>Citrobacter freundii</i> complex	<i>Enterobacter</i> cloacae complex	<i>Escherichia coli</i>	<i>Escherichia coli</i> , ESBL	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Proteus mirabilis</i>	<i>Pseudomonas aeruginosa</i>	<i>Stenotrophomonas maltophilia</i>
Isolates (N)	31 <sup>a</sup>	48 <sup>a</sup>	710	27 <sup>b</sup>	42 <sup>a</sup>	36	35	66	34 <sup>a</sup>
<b>Antibiotic</b>	<b>Susceptible (%)</b>								
Ampicillin	R	R	58	*	R	R	89	R	R
Ampicillin/ Sulbactam	R	R	66	*	70	89	-	R	R
Amoxicillin/Clavulanate	R	R	89	*	89 <sup>b</sup>	95 <sup>b</sup>	100 <sup>b</sup>	R	R
Piperacillin/ Tazobactam	90	90	96	*	88	97	97	99	R
Cefazolin (not uUTI)	R	R	68	*	-	91	15	R	R
Cefazolin (uUTI)	R	R	98	*	-	96	100	R	R
Ceftazidime	-	-	98	*	100	-	-	100	-
Ceftriaxone	-	-	99	*	93	97	94	R	R
Cefepime	100	96	100	*	98	100	94	100	R
Aztreonam	-	-	-	*	-	-	-	90	R
Ertapenem	100	98	100	100	100	100	100	R	R
Meropenem	-	-	-	-	-	-	-	97	R
Ciprofloxacin	93	96	84	25	100	92	89	89	-
Levofloxacin	93	92	85	22	100	92	89	86	94
Gentamicin	96	96	92	74	98	97	89	R	R
Tobramycin	100	96	92	66	98	97	100	96	R
Trimethoprim/ Sulfamethoxazole	93	94	79	37	93	89	89	R	85
Nitrofurantoin <sup>c</sup>	90	25	98	96	91	22	R	-	-

a) Isolates from 2024-2025

b) < 30 isolates or subset of total isolates; results may not be statistically significant

c) urine only

-) not tested, not reported, or insufficient data

\*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant; treatment not recommended

**% Susceptible ≥ 90**

% Susceptible ≥ 80-89

% Susceptible 60-89

% Susceptible < 60 or R

Traffic light color palette

# Sanford Health South Region Pediatric Antibigram

## Gram Negative Organisms

2026 Pediatric Antibigram (Jan-Dec 2025 data)	Citrobacter freundii complex	Enterobacter cloacae complex	Escherichia coli	Escherichia coli, ESBL	Klebsiella oxytoca	Klebsiella pneumoniae	Proteus mirabilis	Pseudomonas aeruginosa	Stenotrophomonas maltophilia
Isolates (N)	31 <sup>a</sup>	48 <sup>a</sup>	710	27 <sup>b</sup>	42 <sup>a</sup>	36	35	66	34 <sup>a</sup>
<b>Antibiotic</b>	<b>Susceptible (%)</b>								
Ampicillin	R	R	58	*	R	R	89	R	R
Ampicillin/ Sulbactam	R	R	66	*	70	89	-	R	R
Amoxicillin/Clavulanate	R	R	89	*	89 <sup>b</sup>	95 <sup>b</sup>	100 <sup>b</sup>	R	R
Piperacillin/ Tazobactam	90	90	96	*	88	97	97	99	R
Cefazolin (not uUTI)	R	R	68	*	-	91	15	R	R
Cefazolin (uUTI)	R	R	98	*	-	96	100	R	R
Ceftazidime	-	-	98	*	100	-	-	100	-
Ceftriaxone	-	-	99	*	93	97	94	R	R
Cefepime	100	96	100	*	98	100	94	100	R
Aztreonam	-	-	-	*	-	-	-	90	R
Ertapenem	100	98	100	100	100	100	100	R	R
Meropenem	-	-	-	-	-	-	-	97	R
Ciprofloxacin	93	96	84	25	100	92	89	89	-
Levofloxacin	93	92	85	22	100	92	89	86	94
Gentamicin	96	96	92	74	98	97	89	R	R
Tobramycin	100	96	92	66	98	97	100	96	R
Trimethoprim/ Sulfamethoxazole	93	94	79	37	93	89	89	R	85
Nitrofurantoin <sup>c</sup>	90	25	98	96	91	22	R	-	-

a) Isolates from 2024-2025

b) < 30 isolates or subset of total isolates; results may not be statistically significant

c) urine only

-) not tested, not reported, or insufficient data

\*) reported as resistant for ESBL; treatment not recommended

R) intrinsically resistant; treatment not recommended

**% Susceptible ≥ 90**

% Susceptible ≥ 80-89

% Susceptible 60-89

% Susceptible < 60 or R

Alternative color palette